A Post Marketing Surveillance on LutatheraÂ® in Patients With Somatostatin Receptor Positive Gastroenteropancreatic Neuroendocrine Tumor in Korea
This is a prospective, open-label, multi-center, non-comparative, non-interventional observational study to assess safety and effectiveness of Lutathera in patients with somatostatin receptor-positive GEP-NET in the real-world setting in Korea.
Somatostatin Receptor-positive GEP-NET
OTHER: Lutathera
Incidence of Adverse Events, Incidence of Adverse Events (AEs), Serious AE and unexpected AEs., Up to 36 weeks|Incidence of Adverse Drug Reactions, Incidence of Adverse Drug Reactions (ADRs), Serious ADRs and unexpected ADRs., Up to 36 weeks
Effectiveness in terms of Overall Response Rate (ORR), ORR is defined as the proportion of treated patients who achieve a best overall response of partial response (PR) or complete response (CR) according to RECIST 1.1.

Partial Response (PR): At least a 30% decrease from baseline, confirmed at 4 weeks.

Complete Response (CR): Disappearance of all known disease, confirmed at 4 weeks, lymph nodes must be less than 10 mm short axis, Up to 32 weeks (4 cycles of 8 weeks)
This is a prospective, open-label, multi-center, non-comparative, non-interventional observational study to assess safety and effectiveness of Lutathera in patients with somatostatin receptor-positive GEP-NET in the real-world setting in Korea.